title: [Efficacy of two Helicobacter pylori eradication treatments in children with recurrent abdominal pain].
abstract: OBJECTIVE
  To compare clinical and bacteriologic efficacy of two therapeutic trials to eradicate Helicobacter pylori (H. pylori) in two series of pediatric patients with recurrent abdominal pain (RAP).
  
  
  METHODS
  n = 36 children with RAP-associated H. pylori infection. Age 9.8 +/- 3.1 years, 19 boys and 17 girls. Clinical and bacteriologic efficacy of two therapeutic trials was compared: Group A (1996-1997), n = 9, amoxicillin, bismuth subsalicilate, and metronidazol, and group B (1991-1993), n = 27, omeprazol, amoxicillin, and clarithromycin. Initially and post-treatment, H. pylori evaluation was carried out with upper endoscopy and gastric biopsies. For statistics, we used Student t test, chi2, Fisher test, and Kruskal-Wallis analysis of variance (alpha = 0.05).
  
  
  RESULTS
  We found that 33/36 cases had gastritis at endoscopy, two with duodenal ulcer; nodular gastritis was observed in more than one half of total cases. All cases fulfilled histologic criteria of gastritis according to Sydney Score. In group A eradication was achieved in 28.6%, while in group B eradication rose to 77.8% (p < 0.05). In group A, 8/9 and in group B 15/27 persisted with RAP (p = 0.113).
  
  
  CONCLUSIONS
  High frequency of abnormal and histologic findings was observed in the series presented on children with RAP and H. pylori. Eradication efficacy in the omeprazol/amoxicillin/clarithromycin group was higher when compared with bismuth subsalicilate/amoxicillin/metronidazol trial. This efficacy is comparable to pediatric series treated with the same therapeutic trial.
authors.affiliation: Servicio de Gastroenterología, Hospital de Pediatría, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, México. larrosa@prodigy.net.mx
authors.forename: Alfredo
authors.initials: A
authors.lastname: Larrosa-Haro
authors.forename: Elsa Ofelia
authors.initials: EO
authors.lastname: Martínez-Puente
authors.forename: Pedro
authors.initials: P
authors.lastname: Coello-Ramírez
authors.forename: Yolanda Alicia
authors.initials: YA
authors.lastname: Castillo de León
authors.forename: María del Carmen
authors.initials: Mdel C
authors.lastname: Bojórquez-Ramos
authors.forename: Rocío
authors.initials: R
authors.lastname: Macías-Rosales
authors.forename: Osvaldo
authors.initials: O
authors.lastname: García-Salazar
authors.forename: Gonzalo
authors.initials: G
authors.lastname: Vázquez-Camacho
authors.forename: María Rosa
authors.initials: MR
authors.lastname: Flores Márquez
mesh_terms: D015746:Abdominal Pain / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D005756:Gastritis / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents